Neurology Central

Additional Alzheimer’s programs eliminated: industry news round-up

The onslaught of terminations for Alzheimer’s research programs continues with announcements from Merck & Co (NJ, USA) and Boehringer Ingelheim (Rhein, Germany), on the other end of the spectrum approvals have been granted for multiple sclerosis (MS) and neurofibromatosis treatments.
Our highlights from the latest neuroscience and neurology industry headlines:
  • Phase III verubecestat trial terminated by Merck & Co.
  • FDA grants delayed approval for MS drug
  • Boehringer Ingelheim scraps Phase II Alzheimer’s program
  • Biogen shares fall after announcing patient additions to aducanumab trial
  • Orphan Drug Designation granted for selumetinib
    Restricted Content / Members Only

    You cannot view this content because It is available to members only. Please or Register to view this area.